Neural Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement and Change of Auditors
Toronto, Ontario--(Newsfile Corp. - October 2, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed the first tranche of the private placement ("Private Placement") for gross proceeds of $293,346.42 and completed debt settlement of approximately $327,845.49 ("Debt Settlement"). Ian Campbell, CEO of Neural Therapeutics commented: "While the capital markets environment for junior life...
2023-10-02 4:30 PM EDT
Neural Therapeutics Receives Key Permission from Peruvian Government to Harvest and Work with the San Pedro Cactus Containing Mescaline
Permission enables company to conduct research with potentially patentable outcomesRare permission granted due to Company's commitment to knowledge transfer and species preservationResearch Partnership with Universidad Peruana Cayetano HerediaToronto, Ontario--(Newsfile Corp. - July 27, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce that after nearly 11 months of a rigorous review process, the Company has received a key permission from Servicio Nacional...
2023-07-27 7:30 AM EDT
Neural Therapeutics Inc. Closes Rights Offering
Toronto, Ontario--(Newsfile Corp. - July 14, 2023) - Neural Therapeutics Inc. (the "Company" or "Neural"), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed its previously announced rights offering which expired on July 7, 2023 (the "Rights Offering").In connection with the closing of the Rights Offering, the Company issued 5,595,992 common shares in the capital of Neural (the "Neural Shares") at the subscription price of $0.03 per Neural...
2023-07-14 5:00 PM EDT
Neural Therapeutics Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to provide the following corporate update, describing the progress made with the execution of the corporate strategy towards developing a mescaline-based psychedelic for mental health treatment.Spin-Out Completed and DTC Eligibility ReceivedOn May 23, 2023, Neural completed its spin-out from Vertical Peak Holdings Inc. (formerly High Fusion Inc.), as a result of which, Neural...
2023-06-20 8:13 AM EDT
Neural Therapeutics Inc. Announces Launch of Rights Offering and Concurrent Private Placement
Toronto, Ontario--(Newsfile Corp. - June 13, 2023) - Neural Therapeutics Inc. (the "Company" or "Neural") an ethnobotanical drug-discovery and development company announces it is undertaking a rights offering to raise gross proceeds of up to $1,184,080 (the "Rights Offering") and a non-brokered private placement of up to $900,000 ("Concurrent Private Placement"). Ian Campbell, CEO of Neural commented: "While the overall capital market conditions for junior life sciences companies continue to...
2023-06-13 5:09 PM EDT